Latest News and Press Releases

1H22 Galafold® Revenue of $159.4M, reflecting 11% Sales Growth with Operational Growth of 18%, Partly Offset by Currency Headwinds of 7% On-Track to Deliver Full-Year Double-Digit Revenue Growth of...

PHILADELPHIA, July 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2022 at...

PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global...

PHILADELPHIA, May 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by 90 days for the...

1Q22 Galafold® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold® Strengthens U.S. Patent Protection into 2038 Advancing U.S. and EU Regulatory Reviews and...

1Q22 Galafold® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold® Strengthens U.S. Patent Protection into 2038 ...

PHILADELPHIA, May 04, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2022 Healthcare...

PHILADELPHIA, April 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30...

PHILADELPHIA, April 19, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...

Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk and Forced Vital Capacity for ERT-Naïve and ERT-Experienced Patients Out to 3 Years Consistent Reduction in Biomarkers Continue...